Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1

Most available neutralizing antibodies are ineffective against highly mutated SARS-CoV-2 Omicron subvariants. Therefore, it is crucial to develop potent and broad-spectrum alternatives to effectively manage Omicron subvariants. Here, we constructed a high-diversity nanobody phage display library and...

書誌詳細
出版年:	Vaccines
主要な著者:	Jiali Wang, Bingjie Shi, Hanyi Chen, Mengyuan Yu, Peipei Wang, Zhaohui Qian, Keping Hu, Jianxun Wang
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2024-04-01
主題:	SARS-CoV-2 Omicron subvariants phage display library receptor-binding domain (RBD) multivalent nanobodies neutralizing activity
オンライン･アクセス:	https://www.mdpi.com/2076-393X/12/4/417

類似資料

The epidemiology and phylogenetic trends of Omicron subvariants from BA.5 to XBB.1 in Taiwan
著者:: Jih-Jin Tsai, 等
出版事項: (2024-11-01)

Enhancing Tumor Immunotherapy by Multivalent Anti‐PD‐L1 Nanobody Assembled via Ferritin Nanocage
著者:: Manman Liu, 等
出版事項: (2024-05-01)

Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters
著者:: Peter J. Halfmann, 等
出版事項: (2024-03-01)

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
著者:: Zhihong Wang, 等
出版事項: (2024-12-01)

Monovalent, bivalent and biparatopic nanobodies targeting S1 protein of porcine epidemic diarrhea virus efficiently neutralized the virus infectivity
著者:: Huai-rui Qin, 等
出版事項: (2024-07-01)

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein
著者:: Qizhong Lu, 等
出版事項: (2021-01-01)

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
著者:: Airu Zhu, 等
出版事項: (2023-03-01)

Does the COVID-19 XBB Omicron subvariant signal the beginning of the end of the pandemic?
著者:: Jinghao Nicholas Ngiam, 等
出版事項: (2024-12-01)

COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2
著者:: Wei-Chun Chen, 等
出版事項: (2023-08-01)

XBB.1.16‐RBD‐based trimeric protein vaccine can effectively inhibit XBB.1.16‐included XBB subvariant infection
著者:: Dandan Peng, 等
出版事項: (2024-09-01)

Multivalent Rhamnose‐Modified EGFR‐Targeting Nanobody Gains Enhanced Innate Fc Effector Immunity and Overcomes Cetuximab Resistance via Recruitment of Endogenous Antibodies
著者:: Yanchun Li, 等
出版事項: (2024-04-01)

Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study
著者:: Carson K. L. Lo, 等
出版事項: (2024-01-01)

XBB.1.16 Omicron subvariant rise to a variant of interest: Implications for global alertness and preparedness
著者:: Okesanya Olalekan John, B'MLS, 等
出版事項: (2023-12-01)

Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies
著者:: Delphine Planas, 等
出版事項: (2023-02-01)

Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment
著者:: Jiewen Wang, 等
出版事項: (2022-01-01)

Can the RBD mutation R346X provide an additional fitness to the “variant soup,” including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance?
著者:: Srijan Chatterjee, 等
出版事項: (2023-06-01)

A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB
著者:: Yuan Ding, 等
出版事項: (2023-03-01)

Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau
著者:: Cong Xu, 等
出版事項: (2023-01-01)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
著者:: Danyi Ao, 等
出版事項: (2023-04-01)

In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics
著者:: Rahatul Islam, 等
出版事項: (2023-08-01)

Mapping the Early Dispersal Patterns of SARS-CoV-2 Omicron BA.4 and BA.5 Subvariants in the Absence of Travel Restrictions and Testing at the Borders in Europe
著者:: Evangelia Georgia Kostaki, 等
出版事項: (2022-12-01)

Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library
著者:: Dmitri Dormeshkin, 等
出版事項: (2022-09-01)

Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort
著者:: Jianliang Huang, 等
出版事項: (2023-10-01)

A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529)
著者:: Lu Y, 等
出版事項: (2023-01-01)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
著者:: Minrun Duan, 等
出版事項: (2023-12-01)

Roadmap on multivalent batteries
著者:: M Rosa Palacin, 等
出版事項: (2024-01-01)

Natural selection of the D614G mutation in SARS-CoV-2 Omicron (B.1.1.529) variant and its subvariants
著者:: Chiranjib Chakraborty, 等
出版事項: (2023-03-01)

Identification of an IGHV3-53-Encoded RBD-Targeting Cross-Neutralizing Antibody from an Early COVID-19 Convalescent
著者:: Yuanyuan Hu, 等
出版事項: (2024-03-01)

A Competitive Panning Method Reveals an Anti-SARS-CoV-2 Nanobody Specific for an RBD-ACE2 Binding Site
著者:: Siqi He, 等
出版事項: (2023-02-01)

Glycodendrimers: tools to explore multivalent galectin-1 interactions
著者:: Jonathan M. Cousin, 等
出版事項: (2015-05-01)

Viral sepsis-induced mortality of older patients infected by the Omicron subvariant BA.5 of SARS-CoV-2: a retrospective study
著者:: Yu Zhang, 等
出版事項: (2025-04-01)

CDR1 Composition Can Affect Nanobody Recombinant Expression Yields
著者:: Marco Orlando, 等
出版事項: (2021-09-01)

Evaluation of Neutralizing Activity against Omicron Subvariants in BA.5 Breakthrough Infection and Three-Dose Vaccination Using a Novel Chemiluminescence-Based, Virus-Mediated Cytopathic Assay
著者:: Mako Toyoda, 等
出版事項: (2023-08-01)

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
著者:: Masayuki Amano, 等
出版事項: (2023-10-01)

The diverse dependence of galectin-1 and -8 on multivalency for the modulation of FGFR1 endocytosis
著者:: Dominika Żukowska, 等
出版事項: (2024-05-01)

Characteristics of the First 284 Patients Infected with the SARS-CoV-2 Omicron BA.2 Subvariant at a Single Center in the Apulia Region of Italy, January–March 2022
著者:: Daniela Loconsole, 等
出版事項: (2022-04-01)

Molecular Evolutionary Analyses of the Spike Protein Gene and Spike Protein in the SARS-CoV-2 Omicron Subvariants
著者:: Norika Nagasawa, 等
出版事項: (2023-09-01)

Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
著者:: Peter Bannas, 等
出版事項: (2017-11-01)

Redistribution and Activation of CD16brightCD56dim NK Cell Subset to Fight against Omicron Subvariant BA.2 after COVID-19 Vaccination
著者:: Huiyun Peng, 等
出版事項: (2023-04-01)

Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
著者:: Masaud Shah, 等
出版事項: (2023-09-01)